What question did this study set out to answer?

To assess long-term survival outcomes and prognostic variables in patients with Ewing's sarcoma treated with local radiotherapy and adjuvant multi-agent chemotherapy regimens.

January 1, 1975Cancer

Combined modality therapy of Ewing's sarcoma

View Full Paper

Ask AI

Bookmark

Why the study?

Does combined modality therapy with local irradiation and intensive systemic chemotherapy improve survival in patients with Ewing's sarcoma?

Population

66 consecutive patients with Ewing's sarcoma treated at the National Cancer Institute since 1964, including…

Comparison

Local irradiation of the primary site combined… vs Previous less intensive chemotherapy protocols.

Design

Case_series

Follow-up

5 years

Authors

TPThomas C. PomeroyNational Institutes of Health RJRalph E. JohnsonGNS Science

Discussion

Member takes

Implication

Supports multimodal therapy consideration in non-metastatic Ewing's sarcoma; leaves open optimal modern regimens and selection criteria.

Key Points

To assess long-term survival outcomes and prognostic variables in patients with Ewing's sarcoma treated with local radiotherapy and adjuvant multi-agent chemotherapy regimens.
Evaluated 66 consecutive patients with Ewing's sarcoma treated with local irradiation of the primary site and adjuvant systemic chemotherapy.
Administered progressively intensified regimens, including an alternating protocol of high-dose adriamycin and cyclophosphamide-vincristine pulses.
Achieved actuarial survival rates of 56% at 2 years and 35% at 5 years across the entire cohort of 66 patients.
Demonstrated 2-year and 5-year survival rates of 64% and 52%, respectively, in the subset of 43 patients presenting without clinically detectable metastases.
Identified presence of initial metastatic disease, primary tumor site, patient age, and systemic symptoms as key prognostic determinants of survival.

Structured PICO

Does combined modality therapy with local irradiation and intensive systemic chemotherapy improve survival in patients with Ewing's sarcoma?

Population

66 consecutive patients with Ewing's sarcoma treated at the National Cancer Institute since 1964, including 43 patients without clinically detectable metastases at diagnosis.

Intervention

Local irradiation of the primary site combined with adjuvant regimens of progressively more intensive systemic chemotherapy (current protocol: alternating high-dose pulses of adriamycin and cyclophosphamide-vincristine).

Comparator

Previous less intensive chemotherapy protocols (historical comparison).

Outcome

Actuarial survival rates (2-year and 5-year).hard clinical

Combined modality therapy with local irradiation and intensive systemic chemotherapy yields a 52% 5-year survival rate in Ewing's sarcoma patients without initial metastases.

Limitations

Problems of diagnostic accuracy in evaluating treatment results
Confounding factors influencing prognosis such as initial metastatic disease, site of the primary tumor, age at diagnosis, and presence of systemic symptoms

Cite This Study

Pomeroy et al. (1975) studied this question.

synapsesocial.com/papers/6a82fac278944653d1e8dc9f https://doi.org/10.1002/1097-0142(197501)35:1<36::aid-cncr2820350106>3.0.co;2-l

View Full Paper

Ask AI

Bookmark

Combined modality therapy of Ewing's sarcoma

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Combined modality therapy of Ewing's sarcoma

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider